Listen "Getting answers on tariffs, China and Trump: What we learned from Q2 earnings"
Episode Synopsis
After three weeks of corporate earnings reports, we’ve got a roundup of news and analysis taking in all of the biotech and pharma companies that gave updates. We’ll dig into what big pharma companies are saying about the Trump administration’s tariff, pricing and regulatory moves, how companies are talking about China and what we learned about closely watched results from a few key companies like Lilly and Novo, a pain drug failure and how big pharma is positioning itself for its patent cliff.
More episodes of the podcast Post-Hoc Live
The plan to make more custom CRISPR therapies — w Kiran Musunuru & Rebecca Ahrens-Nicklas
03/11/2025
The fight over Metsera
03/11/2025
Breaking down the XBI — with Josh Schimmer
10/09/2025
Choosing the Endpoints 11
03/09/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.